Schizophrenia risk genes: Implications for future drug development and discovery

Biochemical Pharmacology

Volumn 81, Issue 12, 2011, Pages 1367-1373

  O'Connell, Garret ^a,b   Lawrie, Stephen M ^a   McIntosh, Andrew M ^a   Hall, Jeremy ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF READING   (United Kingdom)

Author keywords

Drugs; Pharmacogenomics; Risk genes; Schizophrenia; Transgenic animal models

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; DEXTRO AMINO ACID OXIDASE INHIBITOR; DEXTRO SERINE; GLUTAMIC ACID; HALOPERIDOL; HISTONE DEACETYLASE INHIBITOR; IMIDAZENIL; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG; VALPROIC ACID;

CLINICAL TRIAL (TOPIC); DAOA GENE; DISC1 GENE; DTNBP1 GENE; EPIGENETICS; GABAERGIC SYSTEM; GENE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC RISK; GRIN2B GENE; HUMAN; NMDAR1 GENE; NONHUMAN; NRG1 GENE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TECHNOLOGY; TRANSCRIPTOMICS; TRANSGENIC ANIMAL; UNSPECIFIED SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; DRUG DISCOVERY; EPIGENESIS, GENETIC; GENOME, HUMAN; HUMANS; RISK FACTORS; SCHIZOPHRENIA;

EID: 79956199179     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.11.009     Document Type: Review

References (106)

1. J. Kane, G. Honigfeld, J. Singer, and H. Meltzer Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine Arch Gen Psych 45 1988 789 796
2. H. Hippius History of clozapine Psychopharmacol 99 1989 53 55
3. D.C. Owens What CATIE did: some thoughts on implications deep and wide Psychiatr Serv 59 2008 530 533
4. M.J. Arranz, J. Munro, J. Birkett, A. Bolonna, D. Mancama, and M. Sodhi Pharmacogenetic prediction of clozapine response Lancet 355 2000 1615 1616 (Pubitemid 30240510)
5. E.J. Nestler, and S.E. Hyman Animal models of neuropsychiatric disorders Nat Neurosci 13 2010 1161 1169
6. T.R. Insel Disruptive insights in psychiatry: transforming a clinical discipline J Clin Invest 119 2009 700 705
7. M.J. Arranz, and J. de Leon Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research Mol Psychiatry 12 2007 707 747 (Pubitemid 47172693)
8. A. Breier Developing drugs for cognitive impairment in schizophrenia Schizophr Bull 31 2005 816 822 (Pubitemid 41437775)
9. B. Hüsing, L. Jäncke, and B. Tag Impact assessment of neuroimaging 2006 IOS Press Amsterdam, Netherlands
10. J. Hall, H.C. Whalley, D.E. Job, B.J. Baig, A.M. McIntosh, and K.L. Evans A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms Nat Neurosci 9 2006 1477 1478 (Pubitemid 44862654)
11. A.M. McIntosh, T.W. Moorhead, D. Job, G.K. Lymer, S. Muñoz Maniega, and J. McKirdy The effects of a neuregulin 1 variant on white matter density and integrity Mol Psychiatry 13 2008 1054 1059
12. E. Sprooten, G.K. Lymer, S.M. Maniega, J. McKirdy, J.D. Clayden, and M.E. Bastin The relationship of anterior thalamic radiation integrity to psychosis risk associated neuregulin-1 variants Mol Psychiatry 14 2009 237 238
13. M.J. Owen, N. Craddock, and M.C. O'Donovan Suggestion of roles for both common and rare risk variants in genome-wide studies of schizophrenia Arch Gen Psychiatry 67 2010 667 673
14. S.A. McCarroll, F.G. Kuruvilla, J.M. Korn, S. Cawley, J. Nemesh, and A. Wysoker Integrated detection and population-genetic analysis of SNPs and copy number variation Nat Genet 40 2008 1166 1174
15. T. Walsh, J.M. McClellan, S.E. McCarthy, A.M. Addington, S.B. Pierce, and G.M. Cooper Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia Science 320 2008 539 543 (Pubitemid 351590668)
16. H. Stefansson, D. Rujescu, S. Cichon, O.P. Pietiläinen, A. Ingason, and S. Steinberg Large recurrent microdeletions associated with schizophrenia Nature 455 2008 232 236
17. International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 2008;455:237-41.
18. G. Kirov, D. Rujescu, A. Ingason, D.A. Collier, M.C. O'Donovan, and M.J. Owen Neurexin 1 (NRXN1) deletions in schizophrenia. Recurrent rearrangements of chromosome 1q21. 1 and variable pediatric phenotypes Schizophr Bull 35 2009 851 854
19. Autism Genome Project Consortium Mapping autism risk loci using genetic linkage and chromosomal rearrangements Nat Genet 39 2007 319 328
20. J.M. Friedman, A. Baross, A.D. Delaney, A. Ally, L. Arbour, and L. Armstrong Oligonucleotide microarray analysis of genomic imbalance in children with mental retardation Am J Hum Genet 79 2006 500 513 (Pubitemid 44384259)
21. H.C. Mefford, A.J. Sharp, C. Baker, A. Itsara, Z. Jiang, and K. Buysse Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes N Engl J Med 359 2008 1685 1699
22. N.M. Williams, I. Zaharieva, A. Martin, K. Langley, K. Mantripragada, and R. Fossdal Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis Lancet 376 2010 1401 1408
23. N. Craddock, M.C. O'Donovan, and M.J. Owen Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology Schizophr Bull 32 2006 9 16 (Pubitemid 43063811)
24. M.C. O'Donovan, N. Craddock, N. Norton, H. Williams, T. Peirce, and V. Moskvina Identification of loci associated with schizophrenia by genome-wide association and follow-up Nat Genet 40 2008 1053 1055
25. Williams HJ, Norton N, Dwyer S, Moskvina V, Nikolov I, Carroll L, et al. Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. Mol Psychiatry 2010; in press.
26. N. Craddock, M.C. O'Donovan, and M.J. Owen Psychosis genetics: modeling the relationship between schizophrenia, bipolar disorder, and mixed (or "'schizoaffective") psychoses Schizophr Bull 35 2009 482 490
27. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661-678.
28. M.L. Hamshere, E.K. Green, I.R. Jones, L. Jones, V. Moskvina, and G. Kirov Genetic utility of broadly defined bipolar schizoaffective disorder as a diagnostic concept Br J Psychiatry 195 2009 23 29
29. Cross-Disorder Phenotype Group of the Psychiatric GWAS Consortium, N. Craddock, K. Kendler, M. Neale, and J. Nurnberger Dissecting the phenotype in genome-wide association studies of psychiatric illness Br J Psychiatry 195 2009 97 99
30. T. Insel, B. Cuthbert, M. Garvey, R. Heinssen, D.S. Pine, and K. Quinn Research domain criteria (RDoC): toward a new classification framework for research on mental disorders Am J Psychiatry 167 2010 748 751
31. K. Iwamoto, and T. Kato Gene expression profiling in schizophrenia and related mental disorders Neuroscientist 12 2006 349 361 (Pubitemid 44050863)
32. S. Mohr, and C.C. Liew The peripheral-blood transcriptome: new insights into disease and risk assessment Trends Mol Med 13 10 2007 422 432 (Pubitemid 47562311)
33. S.J. Glatt, I.P. Everall, W.S. Kremen, J. Corbeil, R. Sásik, and N. Khanlou Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia Proc Natl Acad Sci USA 102 2005 15533 15538 (Pubitemid 41528092)
34. N.E. Savaskan, A.U. Bräuer, M. Kühbacher, I.Y. Eyüpoglu, A. Kyriakopoulos, and Ninnemann Selenium deficiency increases susceptibility to glutamate-induced excitotoxicity FASEB J 17 2003 112 114
35. T. Kanazawa, G. Chana, S.J. Glatt, H. Mizuno, E. Masliah, and H. Yoneda The utility of SELENBP1 gene expression as a biomarker for major psychotic disorders: replication in schizophrenia and extension to bipolar disorder with psychosis Am J Med Genet B: Neuropsychiatr Genet 147B 2008 686 689
36. S. Amar, O. Ovadia, W. Maier, R. Ebstein, R.H. Belmaker, and D. Mishmar Copy number variation of the SELENBP1 gene in schizophrenia Behav Brain Funct 6 2010 40
37. S.J. Glatt, S.D. Chandler, C.A. Bousman, G. Chana, G.R. Lucero, and E. Tatro Alternatively spliced genes as biomarkers for schizophrenia. Bipolar disorder and psychosis: a blood-based spliceome-profiling exploratory study Curr Pharmacogenomics Person Med 7 2009 164 188
38. D.J. Crowther Applications of microarrays in the pharmaceutical industry Curr Opin Pharmacol 2 2002 551 554
39. K.E. Stephan, K.J. Friston, and C.D. Frith Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring Schizophr Bull 35 2009 509 527
40. P.J. Harrison, and D.R. Weinberger Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence Mol Psychiatry 10 2005 40 68 (Pubitemid 40139588)
41. J. Hall, L. Romaniuk, A.M. McIntosh, J.D. Steele, E.C. Johnstone, and S.M. Lawrie Associative learning and the genetics of schizophrenia Trends Neurosci 32 2009 359 365
42. H.J. Chiu, Y.C. Wang, Y.J. Liou, I.C. Lai, and J.Y. Chen Association analysis of the genetic variants of the N-methyl d-aspartate receptor subunit 2b (NR2b) and treatment-refractory schizophrenia in the Chinese Neuropsychobiology 47 2003 178 181
43. D.C. Goff, G. Tsai, D.S. Manoach, and J.T. Coyle Dose-finding trial of d-cycloserine added to neuroleptics for negative symptoms in schizophrenia Am J Psychiatry 152 1995 1213 1215
44. J.T. Coyle, and G. Tsai The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia Psychopharmacology (Berl) 174 2003 32 38 (Pubitemid 38925088)
45. S.T. Patil, L. Zhang, F. Martenyi, S.L. Lowe, K.A. Jackson, and B.V. Andreev Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial Nat Med 13 2007 1102 1107 (Pubitemid 47517511)
46. D.R. Weinberger Schizophrenia drug says goodbye to dopamine Nat Med 13 2007 1018 1019 (Pubitemid 47517494)
47. D. Inta, H. Monyer, R. Sprengel, A. Meyer-Lindenberg, and P. Gass Mice with genetically altered glutamate receptors as models of schizophrenia: a comprehensive review Neurosci Biobehav Rev 34 2010 285 294
48. M. Williams Commentary: genome-based CNS drug discovery: d-amino acid oxidase (DAAO) as a novel target for antipsychotic medications: progress and challenges Biochem Pharmacol 78 2009 1360 1365
49. I. Chumakov, M. Blumenfeld, O. Guerassimenko, L. Cavarec, M. Palicio, and H. Abderrahim Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia Proc Natl Acad Sci USA 99 2002 13675 13680 (Pubitemid 35215440)
50. R. Abou Jamra, C. Schmael, S. Cichon, M. Rietschel, J. Schumacher, and M.M. Nöthen The G72/G30 gene locus in psychiatric disorders: a challenge to diagnostic boundaries? Schizophr Bull 32 2006 599 608 (Pubitemid 44412845)
51. T. Adage, A.C. Trillat, A. Quattropani, D. Perrin, L. Cavarec, and J. Shaw In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties Eur Neuropsychopharmacol 18 2008 200 214
52. S.M. Smith, J.M. Uslaner, L. Yao, C.M. Mullins, N.O. Surles, and S.L. Huszar The behavioral and neurochemical effects of a novel d-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b] pyrrole-5-carboxylic acid] and d-serine J Pharmacol Exp Ther 328 2009 921 930
53. K. Hashimoto, Y. Fujita, M. Horio, S. Kunitachi, M. Iyo, and D. Ferraris Co-administration of a d-amino acid oxidase inhibitor potentiates the efficacy of d-serine in attenuating prepulse inhibition deficits after administration of dizocilpine Biol Psychiatry 65 2009 1103 1106
54. D. Ferraris, B. Duvall, Y.S. Ko, A.G. Thomas, C. Rojas, and P. Majer Synthesis and biological evaluation of d-amino acid oxidase inhibitors J Med Chem 51 2008 3357 3359 (Pubitemid 351874993)
55. S.M. Smith, J.M. Uslaner, and P.H. Hutson The therapeutic potential of d-amino acid oxidase (DAAO) Inhibitors Open Med Chem J 4 2010 3 9
56. J. Shi, J.A. Badner, E.S. Gershon, L. Chunyu, V.L. Willour, and J.B. Potash Further evidence for an association of G72/G30 with schizophrenia in Chinese Schizophr Res 107 2009 324 326
57. A. Corvin, K.A. McGhee, K. Murphy, G. Donohoe, J.M. Nangle, and S. Schwaiger Evidence for association and epistasis at the DAOA/G30 and d-amino acid oxidase loci in an Irish schizophrenia sample Am J Med Genet B: Neuropsychiatr Genet 144B 2007 949 953 (Pubitemid 47547998)
58. J. Hall, H.C. Whalley, T.W. Moorhead, B.J. Baig, A.M. McIntosh, and D.E. Job Genetic variation in the DAOA (G72) gene modulates hippocampal function in subjects at high risk of schizophrenia Biol Psychiatry 64 2008 428 433
59. J.G. Mulle, K.V. Chowdari, V. Nimgaonkar, and A. Chakravarti No evidence for association to the G72/G30 locus in an independent sample of schizophrenia families Mol Psychiatry 10 2005 431 433
60. K. Ohi, R. Hashimoto, Y. Yasuda, T. Yoshida, H. Takahashi, and N. Iike Association study of the G72 gene with schizophrenia in a Japanese population: a multicenter study Schizophr Res 109 2009 80 85
61. N.M. Williams, E.K. Green, S. Macgregor, S. Dwyer, N. Norton, and H. Williams Variation at the DAOA/G30 locus influences susceptibility to major mood episodes but not psychosis in schizophrenia and bipolar disorder Arch Gen Psychiatry 63 2006 366 373
62. F.M. Benes, and S. Berretta GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder Neuropsychopharmacology 25 2001 1 27 (Pubitemid 32493819)
63. S.G. Roa, G.V. Williams, and P.S. Goldman-Rakic Isodirectional tuning of pyramidal cells by somatic feed-forward inhibition Science 81 1999 1903 1916
64. J.T. Coyle The GABA-glutamate connection in schizophrenia: which is the proximate cause? Biochem Pharmacol 68 2004 1507 1514 (Pubitemid 39286454)
65. C.L. Bodarky, T.B. Halene, R.S. Ehrlichman, A. Banerjee, R. Ray, and C.G. Hahn Novel environment and GABA agonists alter event-related potentials in N-methyl-d-aspartate NR1 hypomorphic and wild-type mice J Pharmacol Exp Ther. 331 2009 308 318
66. W.T. Carpenter Jr., R.W. Buchanan, B. Kirkpatric, and A.F. Breier Diazepam treatment of early signs of exacerbation in schizophrenia Am J Psychiatry 156 1999 299 303 (Pubitemid 29077122)
67. L. Tremolizzo, G. Carboni, W.B. Ruzicka, C.O. Mitchell, I. Sugaya, and P. Tueting An epigenetic mouse model for epigenetic molecular and behavioral neuropathologies related to schizophrenia vulnerability Proc Natl Acad Sci USA 99 2002 17095 17100 (Pubitemid 36034104)
68. L. Tremolizzo, M.S. Doueiri, E. Dong, D.R. Grayson, G. Pinna, and P. Tueting Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice Biol Psychiatry 57 2005 500 509 (Pubitemid 40311985)
69. C.L. Bodarky, T.B. Halene, R.S. Ehrlichman, A. Banerjee, R. Ray, and C.G. Hahn Novel environment and GABA agonists alter event-related potentials in N-methyl-d-aspartate NR1 hypomorphic and wild-type mice J Pharmacol Exp Ther 331 2009 308 318
70. S.L. Eastwood, and P.J. Harrison Cellular basis of reduced reelin expression in schizophrenia Am J Psych 163 2006 540 542 (Pubitemid 44469402)
71. A. Guidotti, J. Auta, J.M. Davis, V. Di Giorgi-Gerevini, Y. Dwivedi, and D.R. Grayson Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study Arch Gen Psych 57 2000 1061 1069
72. W.B. Ruzicka, A. Zhubi, M. Veldic, D.R. Grayson, E. Costa, and A. Guidotti Selective epigenetic alteration of layer I GABAergic neurons isolated from prefrontal cortex of schizophrenia patients using laser-assisted microdissection Mol Psych 12 2007 285 297
73. Y. Chen, U. Beffert, M. Ertunc, T.S. Tang, E.T. Kavalali, and I. Bezprozvanny Reelin modulates NMDA receptor activity in cortical neurons J Neurosci 25 2005 8209 8216 (Pubitemid 41292115)
74. A.M. Addington GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss Mol Psychiatry 10 2005 581 588 (Pubitemid 40897042)
75. K.D. Robertson DNA methylation and human disease Nat Rev Genet 6 2005 597 610 (Pubitemid 41044297)
76. A. Bird DNA methylation patterns and epigenetic memory Genes Dev 16 2002 6 21 (Pubitemid 34049633)
77. M. Veldic, H.J. Caruncho, W.S. Liu, J. Davis, R. Satta, and D.R. Grayson DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains Proc Natl Acad Sci USA 101 2004 348 353 (Pubitemid 38084253)
78. M. Veldic, A. Guidotti, E. Maloku, J.M. Davis, and E. Costa In psychosis, cortical interneurons overexpress DNA-methyltransferase 1 Proc Natl Acad Sci USA 102 2005 2152 2157 (Pubitemid 40262027)
79. D.R. Grayson, Y. Chen, E. Dong, M. Kundakovic, and A. Guidotti From trans-methylation to cytosine methylation. Evolution of the methylation hypothesis of schizophrenia Epigenetics 4 2009 144 149
80. B. Brueckner, and F. Lyko DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy Trends Pharmacol Sci 25 2004 551 554 (Pubitemid 39371143)
81. A. Wassef, J. Baker, and L.D. Kochan GABA and schizophrenia: a review of basic science and clinical studies J Clin Psychopharmacol 23 2003 601 640 (Pubitemid 37443192)
82. J. Munro, P. Matthiasson, S. Osborne, M. Travis, S. Purcell, and A.M. Cobb Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine Acta Psychiatr Scand 110 2004 292 298 (Pubitemid 39278988)
83. E. Dong, R.C. Agis-Balboa, M.V. Simonini, D.R. Grayson, E. Costa, and A. Guidotti Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine induced mouse model of schizophrenia Proc Natl Acad Sci USA 102 2005 12578 12583 (Pubitemid 41266401)
84. E. Costa, J. Davis, C. Pesold, P. Tueting, and A. Guidotti The heterozygote reeler mouse as a model for the development of a new generation of antipsychotics Curr Opin Pharmacol 2 2002 56 62
85. M.V. Simonini, L.M. Camargo, E. Dong, E. Maloku, M. Veldic, and E. Costa The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases Proc Natl Acad Sci USA 103 2006 1587 1592 (Pubitemid 43191209)
86. A. Guidotti, E. Dong, M. Kundakovic, R. Satta, D.R. Grayson, and E. Costa Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling Trends Pharmacol Sci 30 2009 55 60
87. E. Dong, A. Guidotti, D.R. Grayson, and E. Costa Histone hyperacetylation induces demethylation of reelin and 67-kDa glutamic acid decarboxylase promoters Proc Natl Acad Sci USA 104 2007 4676 4681 (Pubitemid 47186284)
88. H.S. Huang, A. Matevossian, C. Whittle, S.Y. Kim, A. Schumacher, and S.P. Baker Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters J Neurosci 27 2007 11254 11262 (Pubitemid 47621326)
89. E. Dong, M. Nelson, D.R. Grayson, E. Costa, and A. Guidotti Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation Proc Natl Acad Sci USA 105 2008 13614 13619
90. A. Fischer, F. Sananbenesi, A. Mungenast, and L.H. Tsai Targeting the correct HDAC(s) to treat cognitive disorders Trends Pharmacol Sci 31 2010 605 617
91. S. Akbarian, and H. Huang Epigenetic regulation in human brain - focus on histone lysine methylation Biol Psychiatry 65 2009 198 203
92. Q. Wang, H. Jaaro-Peled, A. Sawa, and N.J. Brandon How has DISC1 enabled drug discovery? Mol Cell Neurosci 37 2008 187 195 (Pubitemid 351173852)
93. D.H. Blackwood, and W.J. Muir Clinical phenotypes associated with DISC1, a candidate gene for schizophrenia Neurotox Res 6 2004 35 41
94. J.K. Millar, S. Mackie, S.J. Clapcote, H. Murdoch, B.S. Pickard, and S. Christie Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illness J Physiol 584 2007 401 405 (Pubitemid 47578327)
95. A. Kamiya, T. Tomoda, J. Chang, M. Takaki, C. Zhan, and M. Morita DISC1-NDEL1/NUDEL protein interaction, an essential component for neurite outgrowth, is modulated by genetic variations of DISC1 Hum Mol Genet 15 2006 3313 3323 (Pubitemid 44642623)
96. J.K. Millar, B.S. Pickard, S. Mackie, R. James, S. Christie, and S.R. Buchanan DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling Science 310 2005 1187 1191 (Pubitemid 41681745)
97. L.M. Camargo, V. Collura, J.C. Rain, K. Mizuguchi, H. Hermjakob, and S. Kerrien Disrupted in Schizophrenia 1 Interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia Mol Psychiatry 12 2007 74 86 (Pubitemid 44973664)
98. C. Kellendonk, E.H. Simpson, and E.R. Kandel Modeling cognitive endophenotypes of schizophrenia in mice Trends Neurosci 32 2009 347 358
99. Ayhan Y, Abazyan B, Nomura J, Kim R, Ladenheim B, Krasnova IN, et al. Differential effects of prenatal and postnatal expressions of mutant human DISC1 on neurobehavioral phenotypes in transgenic mice: evidence for neurodevelopmental origin of major psychiatric disorders. Mol Psychiatry 2010; in press.
100. X. Duan, J.H. Chaung, S. Ge, R.L. Faulkner, J.Y. Kim, and Y. Kitabatake Disrupted-in-schizophrenia 1 regulates integration of newly generated neurons in the adult brain Cell 130 2007 1146 1158 (Pubitemid 47422304)
101. M.V. Pletnikov, Y. Ayhan, Y. Xu, O. Nikolskaia, M. Ovanesov, and H. Huang Enlargement of the lateral ventricles in mutant DISC1 transgenic mice Mol Psychiatry 13 2008 115
102. S.J. Clapcote, T.V. Lipina, J.K. Millar, S. Mackie, S. Christie, and F. Ogawa Behavioral phenotypes of Disc1 missense mutations in mice Neuron 54 2007 387 402 (Pubitemid 46671409)
103. Mouaffak F, Kebir O, Chayet M, Tordjman S, Vacheron MN, Millet B, et al. Association of Disrupted in Schizophrenia 1 (DISC1) missense variants with ultra-resistant schizophrenia. Pharmacogenomics J 2010; in press.
104. Q. Wanga, H. Jaaro-Peledb, A. Sawab, and N.J. Brandon How has DISC1 enabled drug discovery? Mol Cell Neurosci 37 2008 187 195 (Pubitemid 351173852)
105. D. Porteous Genetic causality in schizophrenia and bipolar disorder: out with the old and in with the new Curr Opin Genet Dev 18 2008 229 234
106. G. Donohoe, D.W. Morris, and A. Corvin The psychosis susceptibility gene ZNF804A: associations, functions, and phenotypes Schizophr Bull 36 2010 904 909